Bulletin
Investor Alert

press release

Nov. 30, 2021, 9:13 a.m. EST

Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference

SAN DIEGO, Nov 30, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. /zigman2/quotes/205669265/composite SRNE +5.31% , announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:

An updated corporate presentation will be available at www.sorrentotherapeutics.com .

About Sorrento Therapeutics, Inc.

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB(TM) library"), immuno-cellular therapies ("DAR-T(TM)"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec(TM)"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD(TM), COVI-AMG(TM), COVISHIELD(TM), COVI-MSC(TM) and COVIDROPS(TM); and diagnostic test solutions, including COVITRACK(TM), COVISTIX(TM) and COVITRACE(TM).

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA(TM)), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido(R) (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido(R) was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com .

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the developments of and expectations for Sorrento's and its subsidiaries' and affiliates' products and technologies. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries' technologies and prospects; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations Contact
Dorman Followwill
Email: mediarelations@sorrentotherapeutics.com

Sorrento(R) and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB(TM), DAR-T(TM), SOFUSA(TM), COVIGUARD(TM), COVI-AMG(TM), COVISHIELD(TM), COVIDROPS(TM), COVI-MSC(TM), COVITRACK(TM), COVITRACE(TM) and COVISTIX(TM) are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA(TM) is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido(R) is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

(C)2021 Sorrento Therapeutics, Inc. All Rights Reserved.

COMTEX_398020084/2471/2021-11-30T09:13:01

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/205669265/composite
US : U.S.: Nasdaq
$ 4.56
+0.23 +5.31%
Volume: 5.25M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.40 billion
Rev. per Employee
$102,257
loading...

Partner Center

Link to MarketWatch's Slice.